AgomAb Therapeutics NV

AgomAb Therapeutics NV

NNASDAQ:AGMB
5.97
USD
-0.39
(-6.13%)
639.24MMarket Cap
Mar 03Next Earn
AgomAb Therapeutics NV
NASDAQ:AGMB
(Nasdaq Stock Market)

Recent

price

5.97

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
EUR
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.22
-0.31
-1.28
-1.28
- -
Basic EPS, GAAP
- -
-0.52
-0.68
-1.31
-1.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
0.87
1.36
3.11
3.86
2.69
5.39
Book Value per Share
0.28
0.77
2.52
3.27
2.1
4.81
Tangible Book Value per Share
49
36
36
36
49
45
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-8
-11
-46
-63
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
21
41
129
165
103
238
Working Capital
1
- -
1
1
1
1
LT Debt
42
66
151
188
131
265
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-14.99
-10.46
-27.25
-39.22
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Jun'26
ST Debt
- -
- -
LT Borrowings
- -
- -
LT Finance Leases
1
1
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
49
49
Market Capitalization
- -
560

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Jun'26
Total Current Assets
121
258
Cash, Cash Equivalents & STI
117
252
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
19
20
Payables & Accruals
10
12
ST Debt
- -
- -
Deferred Revenue
1
1

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-30.4%
Free Cash Flow
- -
- -
8.93%
Net Income, GAAP
- -
- -
35.19%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
-0.24
-1.28
2025
- -
- -
-1.28
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
AgomAb Therapeutics N.V. American Depositary Shares, a Belgium-based clinical-stage biopharmaceutical company, focuses on developing disease-modifying therapies for immunology and inflammatory diseases with an emphasis on fibrotic indications and unmet medical needs. The company advances a focused pipeline of novel monoclonal antibodies and small molecules designed to modulate fibrosis pathways, including AGMB-101, an HGF-mimetic antibody targeting MET signaling to promote antifibrotic and regenerative effects; AGMB-129, an ALK-5 inhibitor aimed at fibrostenotic Crohn’s disease; and additional preclinical programs targeting fibrosis, inflammatory, and metabolic conditions. AgomAb retains exclusive worldwide development and commercialization rights for all product candidates and preclinical programs. Founded in 2017, the company is headquartered in Antwerp, Belgium, with its corporate structure organized as a cross-border, clinical-stage biotechnology entity pursuing global development and strategic collaborations. AgomAb pursues partnerships and financing to accelerate clinical progression, expand its pipeline, and broaden its global reach across immunology and fibrotic diseases. The company’s operating activities cover research and development, preclinical and translational studies, and early-phase clinical trials, with a business model oriented toward forging strategic alliances, securing milestone-driven funding, and building a diversified portfolio of disease-modifying therapies. AGMB aims to establish a commercial footprint in major markets through collaborations and potential future U.S. and European listings to support regulatory submissions and product launches.

Company News

  • Agomab to Participate in Upcoming Investor Conferences

  • Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

  • AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript

  • Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial

  • Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

  • AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50

  • AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis

  • Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

  • Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

  • Agomab to Participate in Upcoming Investor Conferences

  • This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

  • Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

  • Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

  • Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

  • Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

  • AgomAb Therapeutics: High Risk, High Reward Stock

  • Agomab Announces Results of Annual General Meeting

  • Agomab Announces Results of Annual General Meeting

  • Agomab to Participate in Upcoming Conferences

  • Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook